Literature DB >> 19408338

Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease.

J Van Limbergen1, R K Russell, E R Nimmo, Y Zhao, H Liao, H E Drummond, G Davies, P M Gillett, P McGrogan, W M Bisset, G Mahdi, D C Wilson, S J Brown, W H I McLean, J Satsangi.   

Abstract

BACKGROUND: Pediatric inflammatory bowel disease (IBD) has a high prevalence of coexistent atopy. Filaggrin (FLG) loss-of-function variants (null-alleles) are associated with eczema and asthma in association with eczema. The aim was to assess the contribution of FLG null-alleles to pediatric IBD susceptibility and to coexistent atopy (eczema, asthma, allergic rhinitis, or food allergy).
METHODS: FLG variants (R501X and 2282del4) were genotyped in 403 children with IBD, 683 parents, and 996 population controls.
RESULTS: In all, 11% of IBD patients carried at least 1 FLG null-allele compared to 11% of population controls (P > 0.4). Carriage of 1 or more null-alleles in patients with atopy (present in 52% of IBD patients) differed from IBD patients without atopy (14% versus 6%, P = 0.01; odds ratio [OR] 2.4, 95% confidence interval [CI] 1.2-5.1). The effect of FLG null-alleles was strongest for eczema (19% versus 7%, P = 0.0003; OR 3.3, 95% CI 1.7-6.6) and food allergy (28% versus 8%, P = 0.0001; OR 4.5, 95% CI 2.0-10.0). The presence of more than 1 atopic disease tended to increase the associated OR: eczema + asthma (23% versus 7%, P = 0.001; OR 3.9, 95% CI 1.6-9.1), eczema + asthma + allergic rhinitis (29% versus 7%, P = 0.0006; OR 5.4, 95% CI 1.9-15.4) and eczema + asthma + allergic rhinitis + food allergy (45% versus 6%, P < 10(-4); OR 12.2, 95% CI 3.2-46.3). Logistic regression analysis of IBD cases confirmed the association of carriage of an FLG null-allele with atopy (P = 0.01; OR 2.4, 95% CI 1.2-5.1) and co-occurrence of different forms of atopy (P = 0.003; OR 3.5, 95% CI 1.5-8.1).
CONCLUSIONS: Filaggrin null-alleles have no effect on IBD susceptibility but contribute to coexistent eczema and food allergy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19408338     DOI: 10.1002/ibd.20926

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  5 in total

Review 1.  One remarkable molecule: filaggrin.

Authors:  Sara J Brown; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

2.  Exome analysis of patients with concurrent pediatric inflammatory bowel disease and autoimmune disease.

Authors:  Gaia Andreoletti; James J Ashton; Tracy Coelho; Claire Willis; Rachel Haggarty; Jane Gibson; John Holloway; Akshay Batra; Nadeem A Afzal; Robert Mark Beattie; Sarah Ennis
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

3.  Atopic children and use of prescribed medication: A comprehensive study in general practice.

Authors:  David H J Pols; Mark M J Nielen; Arthur M Bohnen; Joke C Korevaar; Patrick J E Bindels
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

4.  Uptake of Chemicals through the Skin: An Important Role of Filaggrin Gene Variants.

Authors:  Silke Schmidt
Journal:  Environ Health Perspect       Date:  2021-03-31       Impact factor: 9.031

5.  Chromosome 11q13.5 variant associated with childhood eczema: an effect supplementary to filaggrin mutations.

Authors:  Gráinne M O'Regan; Linda E Campbell; Heather J Cordell; Alan D Irvine; W H Irwin McLean; Sara J Brown
Journal:  J Allergy Clin Immunol       Date:  2010-01       Impact factor: 10.793

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.